Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia

Clinical Cancer Research

Volumn 15, Issue 22, 2009, Pages 7053-7060

  Bonanni, Bernardo ^a   Serrano, Davide ^a   Gandini, Sara ^a   Guerrieri Gonzaga, Aliana ^a   Johansson, Harriet ^a   Macis, Debora ^a   Cazzaniga, Massimiliano ^a   Luini, Alberto ^a   Cassano, Enrico ^a   Oldani, Sabina ^a   Lien, Ernst A ^b,c   Pelosi, Giuseppe ^a   Decensi, Andrea ^a,d  

^a UNIVERSITY OF MILAN   (Italy)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

^d GALLIERA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ANASTROZOLE; ANTITHROMBIN III; C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; CYTOCHROME P450 2D6; ENDOXIFEN; ESTRADIOL; ESTRONE SULFATE; KI 67 ANTIGEN; NOMAFEN; NORTAMOXIFEN; OSTEOCALCIN; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TAMOXIFEN; TAMOXIFEN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; ENDOMETRIUM CANCER; FEMALE; FRACTURE; GENOTYPE; HUMAN; INTRADUCTAL CARCINOMA; IRON DEFICIENCY ANEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; HUMANS; NITRILES; PHARMACOGENETICS; PRECANCEROUS CONDITIONS; RISK; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 72549116842     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1354     Document Type: Article

References (49)

1. Baum M, Buzdar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-2139 (Pubitemid 34694019)
2. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-2757 (Pubitemid 43016814)
3. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349: 1793-1802 (Pubitemid 37362955)
4. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366:455-462 (Pubitemid 41111693)
5. Cuzick J. Chemoprevention of breast cancer. Breast Cancer 2008;15:10-16
6. Dowsett M, Martin LA, Smith I, Johnston S. Mechanisms of resistance to aromatase inhibitors. J Steroid Biochem Mol Biol 2005;95:167-172
7. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758-3767 (Pubitemid 30846221)
8. Dowsett M, Tobias JS, Howell A, et al. The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. Br J Cancer 1999;79:311-315 (Pubitemid 29002301)
9. Dowsett M, Cuzick J, Howell A, Jackson I. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. Br J Cancer 2001;85:317-324
10. Decensi A, Robertson C, Viale G, et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 2003;95:779-790
11. Guerrieri-Gonzaga A, Baglietto L, Johansson H, et al. Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial. Cancer Epidemiol Biomarkers Prev 2001;10:967-970 (Pubitemid 32844905)
12. Lien EA, Solheim E, Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 1991;51:4837-4844
13. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005;23:9312-9318
14. Bonanni B, Macis D, Maisonneuve P, et al. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data fromthe Italian Tamoxifen Trial. J Clin Oncol 2006;24:3708-3709
15. Gerdhem P, Ivaska KK, Alatalo SL, et al. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 2004;19:386-393
16. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-616 (Pubitemid 34498648)
17. Renehan AG, Egger M, Minder C, O'Dwyer ST, Shalet SM, Zwahlen M. IGF-I, IGF binding protein- 3 and breast cancer risk: comparison of 3 meta-analyses. Int J Cancer 2005;115:1006-1007
18. Kaaks R, Lundin E, Rinaldi S, et al. Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control 2002;13:307-316 (Pubitemid 34553511)
19. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843 (Pubitemid 30165206)
20. Vogel VG. Can statin therapy reduce the risk of breast cancer? J Clin Oncol 2005;23:8553-8555
21. Decensi A, Gandini S, Serrano D, et al. Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users. J Clin Oncol 2007;25:4201-4209 (Pubitemid 47548559)
22. Gjerde J, Kisanga ER, Hauglid M, Holm PI, Mellgren G, Lien EA. Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry. J Chromatogr A 2005;1082:6-14.
23. Johansson H, Bonanni B, Mariette F, et al. Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer. Breast Cancer Res Treat 2006;98:167-172 (Pubitemid 44050765)
24. Shiozawa T, Li SF, Nakayama K, Nikaido T, Fujii S. Relationship between the expression of cyclins/cyclin-dependent kinases and sex-steroid receptors/Ki67 in normal human endometrial glands and stroma during the menstrual cycle. Mol Hum Reprod 1996;2:745-752
25. Decensi A, Fontana V, Bruno S, Gustavino C, Gatteschi B, Costa A. Effect of tamoxifen on endometrial proliferation. J Clin Oncol 1996;14:434-440
26. Benjamini Y, Hochberg Y. Controlling the false discovery rates: a practical and powerful approach to multiple testing. J R Stat Soc B 1995; 35:289-300.
27. Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006;21:1215-1223 (Pubitemid 44128334)
28. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53.
29. Lenora J, Ivaska KK, Obrant KJ, Gerdhem P. Prediction of bone loss using biochemical markers of bone turnover. Osteoporos Int 2007;18: 1297-1305 (Pubitemid 47300283)
30. Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 2007;41:346-352
31. Zidan J, Keidar Z, Basher W, Israel O. Effects of tamoxifen on bone mineral density and metabolism in postmenopausal women with early-stage breast cancer. Med Oncol 2004;21:117-121 (Pubitemid 39108001)
32. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351:1393-1396 (Pubitemid 28209997)
33. Punglia RS, Burstein HJ, Winer EP, Weeks JC. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst 2008;100:642-648
34. Sivridis E, Giatromanolaki A. Proliferative activity in postmenopausal endometrium: the lurking potential for giving rise to an endometrial adenocarcinoma. J Clin Pathol 2004;57:840-844 (Pubitemid 39061433)
35. Elkas J, Armstrong A, Pohl J, Cuttitta F, Martinez A, Gray K. Modulation of endometrial steroid receptors and growth regulatory genes by tamoxifen. Obstet Gynecol 2000;95:697-703. (Pubitemid 30210054)
36. Mourits MJ, ten Hoor KA, van der Zee AG, Willemse PH, de Vries EG, Hollema H. The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium. J Clin Pathol 2002;55:514-519
37. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996;14:78-84. (Pubitemid 26022463)
38. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295:2727-2741
39. Guerrieri-Gonzaga A, Robertson C, Bonanni B, et al. Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of lowdose tamoxifen and fenretinide for breast cancer prevention in premenopausal women. J Clin Oncol 2006;24:129-135 (Pubitemid 46630503)
40. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388
41. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998;83:1142-1152 (Pubitemid 28419067)
42. Chen S, Masri S, Wang X, Phung S, Yuan YC, Wu X. What do we know about the mechanisms of aromatase inhibitor resistance? J Steroid Biochem Mol Biol 2006;102:232-240
43. Osipo C, Gajdos C, Cheng D, Jordan VC. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. J Steroid Biochem Mol Biol 2005;93:249-256
44. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360:679-691
45. Brufsky A, Bundred N, Coleman R, et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 2008;13:503-514 (Pubitemid 351872868)
46. Cuzick J. IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther 2008;8:1377-1385
47. Frank DH, Kimler BF, Fabian CJ, et al. Digital image analysis of breast epithelial cells collected by random periareolar fine-needle aspirates (RPFNA) from women at high risk for breast cancer taking hormone replacement and the aromatase inhibitor, letrozole, for six months. Breast Cancer Res Treat 2009;115:661-668
48. Yusuf S, Pais P, Afzal R, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009;373:1341-1351
49. Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006;114:1028-1035